Incyte (INCY): next trial readout expected around 2026-09-01
$INCY · Incyte CorporationTrials that could report in the next 12 months: 21BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything INCY is running — see methodology.
- 2026-09-01in 2wTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- 2026-09-03in 2wA Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
- 2026-09-28in 6wA Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
- 2026-10-09in 7wStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
- 2026-10-09in 7wStudy to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
- 2026-10-19in 9wA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
- 2026-10-19in 9wA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
- 2026-10-19in 9wA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
- 2026-11-05in 11wRollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
- 2026-11-20in 13wA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
- 2026-12-09in 16wStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
- 2026-12-26in 18wA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
- 2027-01-01in 19wA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- 2027-01-04in 20wA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
- 2027-01-06in 20wA Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
- 2027-03-27in 31wA Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- 2027-04-13in 34wA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
- 2027-04-27in 36wA Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- 2027-04-30in 36wSafety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- 2027-04-30in 36wA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
- 2027-06-01in 41wA Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combinati… | Phase 2 | Active Not Recruitingenrolled, still running | 2027-06-01 | NCT06388564 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelo… | Phase 1 | Active Not Recruitingenrolled, still running | 2027-04-30 | NCT04279847 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Ch… | Phase 3 | Recruitingstill enrolling patients | 2027-04-30 | NCT06804811 |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian … | Phase 2 | Recruitingstill enrolling patients | 2027-04-27 | NCT07023627 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When A… | Phase 1 | Recruitingstill enrolling patients | 2027-04-13 | NCT07559474 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metast… | Phase 1 | Active Not Recruitingenrolled, still running | 2027-03-27 | NCT06818812 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With … | Phase 1 | Active Not Recruitingenrolled, still running | 2027-01-06 | NCT06843408 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When A… | Phase 1 | Recruitingstill enrolling patients | 2027-01-04 | NCT07559396 |
+ 13 more tracked trials
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study to Evaluate INCB161734 in Participants With Advanced or Metast… | Phase 1 | Recruitingstill enrolling patients | 2027-01-01 | NCT06179160 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib … | Phase 3 | Active Not Recruitingenrolled, still running | 2026-12-26 | NCT06212999 |
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Ad… | Phase 1 | Recruitingstill enrolling patients | 2026-12-09 | NCT07049575 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in P… | Phase 2 | Active Not Recruitingenrolled, still running | 2026-11-20 | NCT05851443 |
| Rollover Study to Provide Continued Treatment for Participants With B-… | Phase 2 | Active Not Recruitingenrolled, still running | 2026-11-05 | NCT04509700 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in P… | Phase 3 | Active Not Recruitingenrolled, still running | 2026-10-19 | NCT06516965 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in P… | Phase 3 | Active Not Recruitingenrolled, still running | 2026-10-19 | NCT06516952 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of … | Phase 1 | Recruitingstill enrolling patients | 2026-10-19 | NCT07448155 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Part… | Phase 3 | Active Not Recruitingenrolled, still running | 2026-10-09 | NCT06959225 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Part… | Phase 3 | Active Not Recruitingenrolled, still running | 2026-10-09 | NCT06958211 |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous… | Phase 2 | Active Not Recruitingenrolled, still running | 2026-09-28 | NCT05888844 |
| A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmac… | Phase 1 | Recruitingstill enrolling patients | 2026-09-03 | NCT07588139 |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed H… | Phase 3 | Active Not Recruitingenrolled, still running | 2026-09-01 | NCT04824092 |
Status-change history
Every ClinicalTrials.gov change recorded for INCY's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is INCY's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is INCY's lead program in?
Phase 3 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.